Intellia Therapeutics, Inc. NTLA 深 沪
等待开盘 01-28 09:30:00 美东时间
14.83
+0.880
+6.31%
华盛通- 最 高17.09
- 今 开16.51
- 成交量 1499.43万股
- 最 低 14.20
- 昨 收 13.95
- 总市值 17.20亿
- 52周最高 28.25
- 市盈率 静 --
- 换手率 0.01%
- 52周最低 5.90
- 委 比 -11.90%
- 总股本 1.16亿
- 历史最高 202.73
- 量 比 1.71
- 振 幅 20.72%
- 历史最低 5.90
- 每 手 1
- 风险率 4.16%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Intellia Therapeutics Announces FDA Removes Clinical Hold On Its Investigational New Drug application For MAGNITUDE-2 Phase 3 Clinical Study Of Nexiguran Ziclumeran
Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that the U.S. Food and Drug Administration (FDA)
01-27 21:03
Intellia Therapeutics Announces FDA Lift of Clinical Hold on MAGNITUDE-2 Phase 3 Clinical Trial in ATTRv-PN
<p>Intellia Therapeutics announced the FDA has lifted the clinical hold on the MAGNITUDE-2 Phase 3 trial of nexiguran ziclumeran (nex-z) for patients with hereditary transthyretin amyloidosis with polyneuropathy (ATTRv-PN), allowing resumed patient enrollment and dosing. The company is engaging with the FDA regarding the ongoing clinical hold on the MAGNITUDE trial for ATTR-CM. The clinical holds were imposed in 2025 after a patient in the MAGNIT...
01-27 13:00
Intellia Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
Intellia Therapeutics将参加于2026年1月14日在旧金山举行的第44届J.P. Morgan Healthcare Conference，并将在当天上午9点PT进行现场网络直播， replay将在公司网站上保留约30天。公司专注于利用CRISPR技术开发创新疗法，以满足未满足的医疗需求。
01-07 12:30
夜读 | 2026年美股该如何操作？“木头姐”最新战略揭晓：押注基因编辑，抛售消费科技！
2026年美股该如何操作？“木头姐”最新战略揭晓：押注基因编辑，抛售消费科技，特斯拉仍为最大持仓！布局详情>>
01-05 23:59
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
On January 1, 2026, Intellia Therapeutics awarded inducement grants of 22,800 RSUs to two new employees under its 2024 Inducement Plan. The RSUs vest annually over three years and were approved by the compensation committee as a material inducement for employment, complying with Nasdaq Listing Rule 5635(c)(4).
01-02 21:01
Cathie Wood's Biotech Trend: Twist, Beam, CRISPR Latest Stock Picks
The massive rotation currently unfolding within ARK Invest suggests that Cathie Wood thinks 2026 will be the year of the genomic revolution.
01-01 06:06
2026美股生物科技板块怎么投资？杰富瑞：关注6大首选、7大潜力和5大并购目标
杰富瑞近日发布了关于 2026 年美股生物科技行业的展望报告，聚焦行业首选投资标的、被低估的潜力企业和潜在并购机会。
2025-12-25 15:40
2026美股生物科技板块怎么投资？杰富瑞：关注这6大首选股、7大潜力标的和5大并购目标
杰富瑞近日发布了关于2026年美股生物科技行业的展望报告，聚焦行业首选投资标的、被低估的潜力企业和潜在并购机会。该行指出，2026年生物科技领域将迎来多项关键临...
2025-12-24 17:33
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Intellia Therapeutics granted inducement stock option grants to three new employees under its 2024 Inducement Plan on December 1, 2025. The grants consist of 12,600 restricted stock units (RSUs), vesting one-third on December 1, 2026; 2027; and 2028. Vesting is contingent on continued employment through the vesting dates. These awards were approved by the company's compensation committee as a material inducement to employment, in accordance with ...
2025-12-05 21:01
